November 2, 2023

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma

Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca and approximately 400 positions in 14 European countries. In the contemplated transaction, Galapagos will receive a €50 million upfront, potential milestone payments […]

admin Health 0 48 sec read
August 8, 2023

Galapagos to review future of Jyseleca

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023 which show that Jyseleca (filgotinib), approved in Europe for rheumatoid arthritis and ulcerative colitis, reached €54.3 million in sales, up by 54% on the like, year-earlier period but below consensus estimates. The […]

admin Health 0 37 sec read
February 3, 2023

New breakthrough in the treatment of rheumatoid arthritis

A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones in patients with rheumatoid arthritis. In this study, the research team studied the possibility of a treatment method targeting mechanisms related to the differentiation process of osteoblasts that melt bones through enzyme […]

admin Health 0 1 min read
September 28, 2022

Key protein that drives rheumatoid arthritis damage

Scientists have identified a protein known as sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis. A chronic disease in which the immune system attacks the body’s own joint tissues, rheumatoid arthritis affects an estimated 1.5 million Americans. Published in the journal Cellular & Molecular Immunology, the discovery sheds new light on the molecular processes that drive […]

admin Health 0 2 min read
May 27, 2022

Older adults with rheumatoid arthritis still undermedicated, despite aggressive guidelines

Despite guidelines that call for early and aggressive treatment of rheumatoid arthritis, a new study suggests many older adults are not prescribed disease-modifying medications for their inflammatory autoimmune disease. Researchers at Michigan Medicine used the National Ambulatory Medical Care Survey to analyze all ambulatory visits for rheumatoid arthritis by adults 65 years of age and older, representing 7.8 million visits […]

admin Health 0 3 min read
January 30, 2022

AbbVie provides update on Rinvoq for the treatment of rheumatoid arthritis in the U.S

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This update follows a Drug Safety Communication (DSC) issued on 1 September, 2021 by the FDA following its final review of the post-marketing study, ORAL Surveillance, evaluating Xeljanz (tofacitinib) in patients with RA. […]

admin Health 0 53 sec read

Recent Posts

Meta

Categories

Archives

Recent Comments